hu-308

HU-308 is a **synthetic, highly selective agonist** of the **cannabinoid receptor type 2 (CB2 receptor)**. It binds with high affinity to CB2 (Ki ~20–23 nM) and displays negligible binding to the CB1 receptor (Ki >10 µM), thereby showing minimal central nervous system psychoactivity. HU-308 acts as an **immunomodulator**: in preclinical studies, it reduces inflammation, promotes Treg differentiation, inhibits Th17 polarization, and demonstrates peripheral anti-inflammatory, antihypertensive, and analgesic effects. It has been used to study therapies for conditions like inflammatory disorders, autoimmune disease, and peripheral pain. HU-308 was developed as a research tool by Raphael Mechoulam’s group in Israel. Its mechanism is mediated through the activation of the CB2 receptor, resulting in modulation of immune and inflammatory pathways, and in animal models, it demonstrates peripheral action without central (CB1-mediated) psychoactivity[1][2][3][4][7][8][10].

Other names

HU-308HU308HU 308((1S,4S,5S)-4-(2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methanol